Inhibition of human dyskerin as a new approach to target ribosome biogenesis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Rocchi, Laura ^a,b   Barbosa, Arménio J M ^a   Onofrillo, Carmine ^a   Del Rio, Alberto ^a,c   Montanaro, Lorenzo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DYSKERIN; CELL CYCLE PROTEIN; DKC1 PROTEIN, HUMAN; MOLECULAR LIBRARY; NUCLEAR PROTEIN; PSEUDOURIDINE; RIBOSOME RNA;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOGENESIS; CATALYSIS; COMPUTER ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR INTERACTION; PROTEIN MODIFICATION; PROTEIN PSEUDOURIDYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; RIBOSOME; VALIDATION PROCESS; ANTAGONISTS AND INHIBITORS; BIOCATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR LIBRARY; NUCLEOTIDE SEQUENCE; PHARMACOLOGY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

BASE SEQUENCE; BIOCATALYSIS; CELL CYCLE PROTEINS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; NUCLEAR PROTEINS; PROTEIN CONFORMATION; PSEUDOURIDINE; RIBOSOMES; RNA, RIBOSOMAL; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904268446     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101971     Document Type: Article

References (49)

1. Montanaro L, Treré D, Derenzini M (2008) Nucleolus, ribosomes, and cancer. Am J Pathol 173: 301-310. Available: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=2475768&tool=pmcentrez&rendertype=abstract. Accessed 10 February 2013.
2. Montanaro L, Treré D, Derenzini M (2012) Changes in ribosome biogenesis may induce cancer by down-regulating the cell tumor suppressor potential. Biochim Biophys Acta 1825: 101-110. Available: http://www.ncbi.nlm. nih.gov/pubmed/22079382. Accessed 10 February 2013.
3. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW (1996) Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 18: 173-179. Available: http://www.ncbi.nlm.nih.gov/pubmed/8934879. Accessed 10 February 2013.
4. Collins K, Mitchell JR (2002) Telomerase in the human organism. Oncogene 21: 564-579. Available: http://www.ncbi.nlm.nih.gov/pubmed/11850781. Accessed 10 February 2013.
5. Drygin D, Rice WG, Grummt I (2010) The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu Rev Pharmacol Toxicol 50: 131-156. Available: http://www.ncbi.nlm.nih.gov/pubmed/20055700. Accessed 10 February 2013.
6. Drygin D, Siddiqui-Jain A, O'Brien S, Schwaebe M, Lin A, et al. (2009) Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res 69: 7653-7661. Available: http://www.ncbi.nlm.nih.gov/pubmed/19738048. Accessed 10 February 2013.
7. Harley CB (2008) Telomerase and cancer therapeutics. Nat Rev Cancer 8: 167-179. Available: http://www.ncbi.nlm.nih.gov/pubmed/18256617. Accessed 10 February 2013.
8. Shay JW, Wright WE (2002) Telomerase: a target for cancer therapeutics. Cancer Cell 2: 257-265. Available: http://www.ncbi.nlm.nih.gov/pubmed/12398889. Accessed 30 January 2013.
9. Montanaro L (2010) Dyskerin and cancer: more than telomerase. The defect in mRNA translation helps in explaining how a proliferative defect leads to cancer. J Pathol 222: 345-349. Available: http://www.ncbi.nlm.nih.gov/pubmed/ 20925138. Accessed 30 March 2012.
10. Montanaro L, Calienni M, Bertoni S, Rocchi L, Sansone P, et al. (2010) Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation. Cancer Res 70: 4767-4777. Available: http://www.ncbi.nlm.nih.gov/ pubmed/20501855. Accessed 2 February 2013.
11. Sieron P, Hader C, Hatina J, Engers R, Wlazlinski a, et al. (2009) DKC1 overexpression associated with prostate cancer progression. Br J Cancer 101: 1410-1416. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 2768451&tool=pmcentrez&rendertype=abstract. Accessed 10 February 2013.
12. Bellodi C, Krasnykh O, Haynes N, Theodoropoulou M, Peng G, et al. (2010) Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res 70: 6026-6035. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2913864&tool= pmcentrez&rendertype=abstract. Accessed 23 January 2014.
13. Alawi F, Lin P, Ziober B, Patel R (2011) Correlation of dyskerin expression with active proliferation independent of telomerase. Head Neck 33: 1041-1051. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 3116033&tool=pmcentrez&rendertype=abstract. Accessed 10 February 2013.
14. Turano M, Angrisani A, De Rosa M, Izzo P, Furia M (2008) Real-time PCR quantification of human DKC1 expression in colorectal cancer. Acta Oncol 47: 1598-1599. Available: http://www.ncbi.nlm.nih.gov/pubmed/18607840. Accessed 10 February 2013.
15. Liu B, Zhang J, Huang C, Liu H (2012) Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis. PLoS One 7: e43147. Available: http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=3418259&tool=pmcentrez&rendertype=abstract. Accessed 10 February 2013.
16. Li S, Duan J, Li D, Yang B, Dong M, et al. (2011) Reconstitution and structural analysis of the yeast box H/ACA RNA-guided pseudouridine synthase. Genes Dev 25: 2409-2421. Available: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=3222906&tool=pmcentrez&rendertype=abstract. Accessed 10 February 2013.
17. Moura Barbosa AJ, Del Rio A (2012) Freely accessible databases of commercial compounds for high- throughput virtual screenings. Curr Top Med Chem 12: 866-877. Available: http://www.ncbi.nlm.nih.gov/pubmed/22352914. Accessed 20 March 2013.
18. Del Rio A, Barbosa AJM, Caporuscio F, Mangiatordi GF (2010) CoCoCo: a free suite of multiconformational chemical databases for high-throughput virtual screening purposes. Mol Biosyst 6: 2122-2128. Available: http://www.ncbi.nlm. nih.gov/pubmed/20694263. Accessed 14 March 2012.
19. Rashid R, Liang B, Baker DL, Youssef O, He Y, et al. (2006) Crystal structure of a Cbf5-Nop10-Gar1 complex and implications in RNA-guided pseudouridylation and dyskeratosis congenita. Mol Cell 21: 249-260. Available: http://www.ncbi.nlm.nih.gov/pubmed/16427014. Accessed 30 March 2012.
20. Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26: 283-291. Available: citeulike-article-id: 4778677.
21. Wang C, Query CC, Meier UT (2002) Immunopurified Small Nucleolar Ribonucleoprotein Particles Pseudouridylate rRNA Independently of Their Association with Phosphorylated Nopp140. Mol Cell Biol 22: 8457-8466. Available: http://mcb.asm.org/cgi/doi/10.1128/MCB.22.24.8457-8466.2002. Accessed 10 February 2013.
22. Rocchi L, Pacilli A, Sethi R, Penzo M, Schneider RJ, et al. (2013) Dyskerin depletion increases VEGF mRNA internal ribosome entry site-mediated translation. Nucleic Acids Res: 1-11. Available: http://www.ncbi.nlm.nih.gov/ pubmed/23821664. Accessed 9 August 2013.
23. Cadman EC, Dix DE, Handschumacher RE (1978) Clinical, biological, and biochemical effect of pyrazofurin. Cancer Res 38: 682-688. Available: http://www.ncbi.nlm.nih.gov/pubmed/272228. Accessed 10 February 2013.
24. Christopherson RI, Lyons SD, Wilson PK (2002) Inhibitors of de novo nucleotide biosynthesis as drugs. Acc Chem Res 35: 961-971. Available: http://www.ncbi.nlm.nih.gov/pubmed/12437321. Accessed 10 February 2013.
25. Edmonson JH, Decker DG, Malkasian GD, Webb MJ (n.d.) Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinoma. Cancer Treat Rep 65: 1127-1129. Available: http://www.ncbi.nlm.nih.gov/pubmed/7296557. Accessed 10 February 2013.
26. Cormier WJ, Hahn RG, Edmonson JH, Eagan RT (n.d.) Phase II study in advanced sarcoma: randomized trial of pyrazofurin versus combination cyclophosphamide, doxorubicin, and cis-dichlorodiammineplatinum(II) (CAP). Cancer Treat Rep 64: 655-658. Available: http://www.ncbi.nlm.nih.gov/pubmed/ 7191779. Accessed 10 February 2013.
27. Gralla RJ, Sordillo PP, Magill GB (1978) Phase II evaluation of pyrazofurin in patients with metastatic sarcoma. Cancer Treat Rep 62: 1573-1574. Available: http://www.ncbi.nlm.nih.gov/pubmed/361228. Accessed 10 February 2013.
28. Carroll DS, Kemeny NE, Gralla RJ (1979) Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma. Cancer Treat Rep 63: 139-140. Available: http://www.ncbi.nlm.nih.gov/pubmed/369686. Accessed 10 February 2013.
29. Vogler WR, Trulock PD (1978) Phase I study of pyrazofurin in refractory acute myelogenous leukemia. Cancer Treat Rep 62: 1569-1571. Available: http://www.ncbi.nlm.nih.gov/pubmed/152146. Accessed 10 February 2013.
30. Nichols WC, Kvols LK, Ingle JN, Edmonson JH, Ahmann DL, et al. (1978) Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy. Cancer Treat Rep 62: 837-839. Available: http://www.ncbi.nlm.nih.gov/pubmed/657166. Accessed 10 February 2013.
31. Gralla RJ, Currie VE, Wittes RE, Golbey RB, Young CW (1978) Phase II evaluation of pyrazofurin in patients with carcinoma of the lung. Cancer Treat Rep 62: 451-452. Available: http://www.ncbi.nlm.nih.gov/pubmed/348315. Accessed 10 February 2013.
32. Budman D, Currie V, Wittes R (1977) Phase II trial of pyrazofurin in malignant melanoma. Cancer Treat Rep 61: 1733-1734. Available: http://www.ncbi.nlm.nih.gov/pubmed/340040. Accessed 10 February 2013.
33. Cummings FJ, Stoller RG, Calabresi P (1979) Clinical trial of weekly pyrazofurin. Cancer Treat Rep 63: 1363-1365. Available: http://www.ncbi.nlm.nih. gov/pubmed/157807. Accessed 10 February 2013.
34. Duan J, Li L, Lu J, Wang W, Ye K (2009) Structural mechanism of substrate RNA recruitment in H/ACA RNA-guided pseudouridine synthase. Mol Cell 34: 427-439. Available: http://www.ncbi.nlm.nih.gov/pubmed/19481523. Accessed 11 February 2013.
35. Hamma T, Ferré-D'Amaré AR (2010) The box H/ACA ribonucleoprotein complex: interplay of RNA and protein structures in post-transcriptional RNA modification. J Biol Chem 285: 805-809. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2801282&tool= pmcentrez&rendertype=abstract. Accessed 12 February 2013.
36. Hoang C, Hamilton CS, Mueller EG, Ferré-D'Amaré AR (2005) Precursor complex structure of pseudouridine synthase TruB suggests coupling of active site perturbations to an RNA-sequestering peripheral protein domain. Protein Sci 14: 2201-2206. Available: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=2279332&tool=pmcentrez&rendertype=abstract. Accessed 20 February 2013.
37. Czudnochowski N, Wang AL, Finer-Moore J, Stroud RM (2013) In human pseudouridine synthase 1 (hPus1), a C-terminal helical insert blocks tRNA from binding in the same orientation as in the Pus1 bacterial homologue TruA, consistent with their different target selectivities. J Mol Biol 425: 3875-3887. Available: http://www.ncbi.nlm.nih.gov/pubmed/23707380. Accessed 28 January 2014.
38. Hamma T, Ferré-D'Amaré AR (2006) Pseudouridine synthases. Chem Biol 13: 1125-1135. Available: http://www.ncbi.nlm.nih.gov/pubmed/17113994. Accessed 28 January 2014.
39. Ganot P, Bortolin ML, Kiss T (1997) Site-specific pseudouridine formation in preribosomal RNA is guided by small nucleolar RNAs. Cell 89: 799-809. Available: http://www.ncbi.nlm.nih.gov/pubmed/9182768. Accessed 23 January 2014.
40. Consortium TU (2012) Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res 40: D71-5. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3245120&tool= pmcentrez&rendertype=abstract. Accessed 9 February 2013.
41. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=102472&tool= pmcentrez&rendertype=abstract.
42. Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, et al. (2010) A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res 38: W695-9. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 2896090&tool=pmcentrez&rendertype=abstract. Accessed 20 February 2013.
43. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815. Available: http://www.ncbi.nlm. nih.gov/pubmed/8254673. Accessed 11 February 2013.
44. Zebarjadian Y, King T, Fournier MJ, Clarke L, Carbon J (1999) Point mutations in yeast CBF5 can abolish in vivo pseudouridylation of rRNA. Mol Cell Biol 19: 7461-7472. Available: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=84741&tool=pmcentrez&rendertype=abstract. Accessed 20 February 2013.
45. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49: 534-553. Available: http://www.ncbi.nlm.nih.gov/pubmed/16420040. Accessed 11 February 2013.
46. Sherman W, Beard HS, Farid R (2006) Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des 67: 83-84. Available: http://www.ncbi.nlm.nih.gov/pubmed/16492153. Accessed 11 February 2013.
47. Ofengand J, Del Campo M, Kaya Y (2001) Mapping pseudouridines in RNA molecules. Methods 25: 365-373. Available: http://www.ncbi.nlm.nih.gov/pubmed/ 11860291. Accessed 20 February 2013.
48. Montanaro L, Brigotti M, Clohessy J, Barbieri S, Ceccarelli C, et al. (2006) Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J Pathol 210: 10-18. Available: http://www.ncbi.nlm.nih.gov/pubmed/16841302. Accessed 23 January 2014.
49. Montanaro L, Calienni M, Ceccarelli C, Santini D, Taffurelli M, et al. (2008) Relationship between dyskerin expression and telomerase activity in human breast cancer. Cell Oncol 30: 483-490. Available: http://www.ncbi.nlm.nih.gov/ pubmed/18936525. Accessed 23 January 2014.